Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RELIEVE-01: Tislelizumab + CRT for Rectal Cancer
NCT06390982Phase 2Not yet recruiting
- Sponsor
- Fudan University
- Start
- May 2024
- Primary completion
- Dec 2025
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of tislelizumab in rectal cancer, sponsored by Fudan University. Planned start May 2024; status: not yet recruiting.
02
Drugs
tislelizumab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT06390982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06390982.